Medicover GmbH

Futó vizsgálatok

• Toboroz

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· 3. fázis· Forrás

• Toboroz

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· 3. fázis· Forrás

• Toboroz

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· 3. fázis· Forrás

• Még nem toboroz

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· 3. fázis· Forrás

• Fut, nem toboroz

  A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

  NCT07176390· 2. fázis· Forrás

• Toboroz

  A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

  NCT07133633· 2. fázis· Forrás

• Fut, nem toboroz

  Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

  NCT06979531· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

  NCT06972459· 3. fázis· Forrás

• Fut, nem toboroz

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.

  2024-516219-25-00· 3. fázis· Forrás

• Fut, nem toboroz

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· 3. fázis· Forrás

• Toboroz

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· 3. fázis· Forrás

• Fut, nem toboroz

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  NCT06617325· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus

  2024-510584-37-00· 2. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· 3. fázis· Forrás

• Meghívásos bevonás

  A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

  NCT04976322· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Lupus (SLE)3 toboroz
• Arthritis psoriatica2 toboroz
• Pikkelysömör1 toboroz
• Sjögren-szindróma1 toboroz
• Spondylitis ankylopoetica (Bechterew-kór)1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Fut, nem toboroz

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· 2. fázis· Forrás

• Lezárult

  A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

  2024-512986-15-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· 3. fázis· Forrás